Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label study of HRS-2189-based combinations in advanced unresectable or metastatic breast cancer
CTR20244182Phase 2Active
- Sponsor
- Shandong Sende
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hrs-2189 in breast cancer, sponsored by Shandong Sende. Started Feb 2025; status: active.
02
Drugs
hrs-2189
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20244182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244182.